1. Catalog
  2. Nodes
  3. a(CHEBI:"nicotinic acetylcholine receptor agonist")

a(CHEBI:"nicotinic acetylcholine receptor agonist")

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
nicotinic acetylcholine receptor agonist
Namespace
chebi
Namespace Version
20180906
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns

Appears in Networks 1

Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System v1.0.0

In-Edges 0

Out-Edges 11

a(CHEBI:"nicotinic acetylcholine receptor agonist") increases bp(GO:cognition) View Subject | View Object

Consistent with these treatments, nicotinic agents improve cognitive deficits of AD patients (20, 158). PubMed:17009926

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

a(CHEBI:"nicotinic acetylcholine receptor agonist") increases sec(a(CHEBI:acetylcholine)) View Subject | View Object

Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA. PubMed:17009926

Appears in Networks:

a(CHEBI:"nicotinic acetylcholine receptor agonist") increases sec(a(CHEBI:dopamine)) View Subject | View Object

Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA. PubMed:17009926

Appears in Networks:

a(CHEBI:"nicotinic acetylcholine receptor agonist") increases sec(a(CHEBI:noradrenaline)) View Subject | View Object

Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA. PubMed:17009926

Appears in Networks:

a(CHEBI:"nicotinic acetylcholine receptor agonist") increases sec(a(CHEBI:serotonin)) View Subject | View Object

Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA. PubMed:17009926

Appears in Networks:

a(CHEBI:"nicotinic acetylcholine receptor agonist") increases sec(a(CHEBI:"glutamate(2-)")) View Subject | View Object

Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA. PubMed:17009926

Appears in Networks:

a(CHEBI:"nicotinic acetylcholine receptor agonist") increases sec(a(CHEBI:"gamma-aminobutyric acid")) View Subject | View Object

Exogenously applied nicotinic agonists enhance and nicotinic antagonists often diminish the release of ACh, dopamine (DA), norepinephrine, and serotonin, as well as glutamate and GABA. PubMed:17009926

Appears in Networks:

a(CHEBI:"nicotinic acetylcholine receptor agonist") increases bp(GO:memory) View Subject | View Object

In general, nicotinic agonists improve certain forms of memory, and nicotinic antagonists and cholinergic lesions impair memory (5, 141–145). PubMed:17009926

Appears in Networks:

a(CHEBI:"nicotinic acetylcholine receptor agonist") increases bp(GO:memory) View Subject | View Object

In animal studies, acute and chronic nicotine administration improves working memory, and nicotinic agonists were found to improve learning and memory in humans and nonhuman primates (145). PubMed:17009926

Appears in Networks:

a(CHEBI:"nicotinic acetylcholine receptor agonist") increases bp(GO:learning) View Subject | View Object

In animal studies, acute and chronic nicotine administration improves working memory, and nicotinic agonists were found to improve learning and memory in humans and nonhuman primates (145). PubMed:17009926

Appears in Networks:

a(CHEBI:"nicotinic acetylcholine receptor agonist") increases path(MESH:Attention) View Subject | View Object

During attention tasks, the nicotinic antagonist, mecamylamine, impaired accuracy or reaction time (151, 152) and nicotinic agonists improved accuracy (153). PubMed:17009926

Appears in Networks:

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.